US FDA allows expanded use of Bristol Myers' cell therapy for blood cancer (updated)

2Seventy Bio

05/04/2024 14:21

(Adds details and background paragraph 2 and 3)
       April 5 (Reuters) - The U.S. Food and Drug
Administration on Friday allowed the use of Bristol-Myers Squibb
 BMY.N  and 2seventybio's  TSVT.O  cell therapy Abecma in less
severely affected patients with a type of blood cancer. 
    The decision comes after a panel of expert advisers voted in
favor of Abecma's use as an earlier treatment for multiple
myeloma, a common form of cancer that affects older adults. 
    Abecma is already approved in the U.S. to treat patients
with multiple myeloma who have received four or more prior lines
of treatment.
    The health regulator is also reviewing cancer cell therapy,
Carvykti, from Johnson & Johnson  JNJ.N  and its partner Legend
Biotech  LEGN.O  for use in less severely affected patients.  
   The FDA is set to make its decision for the same by April 5.
   Abecma and Carvykti belong to a class of treatments known as
chimeric antigen receptor (CAR) T-cell therapies that work by
modifying white blood cells known as T-cells to attack cancer.
    

 (Reporting by Sneha S K, Bhanvi Satija and Sriparna Roy in
Bengaluru; Editing by Sriraj Kalluvilaand Krishna Chandra Eluri)
 ((Sneha.SK@thomsonreuters.com;))